The dual role of SGLT2 inhibitors: glycemic control and cardioprotection in anthracycline-treated cancer patients
International Journal of Physiology, Pathophysiology and Pharmacology · 2025
DOI: 10.62347/gaxz3059 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Physiology, Pathophysiology and Pharmacology, 2025. Verfasst von Azad Mojahedi. Beteiligte Einrichtung: Department of Internal Medicine, Stony Brook University Hospital New York, United States. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Stony Brook University Hospital New York, United States.
Zitieren
APA
Mojahedi, A. (2025). The dual role of SGLT2 inhibitors: glycemic control and cardioprotection in anthracycline-treated cancer patients. International Journal of Physiology, Pathophysiology and Pharmacology. https://doi.org/10.62347/gaxz3059
Vancouver
Mojahedi A. The dual role of SGLT2 inhibitors: glycemic control and cardioprotection in anthracycline-treated cancer patients. International Journal of Physiology, Pathophysiology and Pharmacology. 2025. doi:10.62347/gaxz3059
BibTeX
@article{Mojahedi2025,
author = {Mojahedi, Azad},
title = {The dual role of SGLT2 inhibitors: glycemic control and cardioprotection in anthracycline-treated cancer patients},
journal = {International Journal of Physiology, Pathophysiology and Pharmacology},
year = {2025},
doi = {10.62347/gaxz3059}
}
EUVIMED